On-line version ISSN 2078-5135
SAMJ, S. Afr. med. j. vol.100 n.5 Cape Town May. 2010
Adrenal suppression and Cushing's syndrome secondary to ritonavir and budesonide
D GrayI; P RouxII; M CarrihillIII; M KleinIV
IMB ChB, DCH, FRACP (Paed). Paediatric HIV Service, Groote Schuur Hospital, Cape Town, and Department of Pulmonology, Red Cross War Memorial Children's Memorial Hospital, Cape Town
IIMB ChB, MPhil (Bioethics), MD, DCH, FCP (Paed). Paediatric HIV Service, Groote Schuur Hospital, and School of Child and Adolescent Health, University of Cape Town
IIIMB ChB, DCH, FCP (Paed), Cert Endo & Metab (SA) Paeds, MPhil (Paeds Endo). Paediatric HIV Service and Department of Paediatric and Adolescent Endocrinology, Groote Schuur Hospital
IVMB ChB, FCP (Paed). School of Child and Adolescent Health, University of Cape Town, and Department of Pulmonology, Red Cross War Memorial Children's Hospital
To the Editor: Ritonavir is a protease inhibitor used in combination therapy for advanced HIV infection. In South Africa lopinavir/ritonavir is first-line therapy for children under 3 years of age where there is a history of perinatal exposure to the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine.1 Ritonavir is a potent inhibitor of hepatic cytochrome P450-CYP3A4 iso-enzyme activity.
Inhaled or intranasal corticosteroids are commonly used in children with recurrent lower airways obstruction, allergic rhinitis and chronic obstructive airways disease. Although systemic absorption of inhaled corticosteroids occurs, sideeffects are uncommon at low or medium doses.
Inhaled corticosteroids are metabolised by hepatic CYP3A4. Fluticasone, a corticosteroid used in children, is known to interact with ritonavir, resulting in high levels of corticosteroids, suppression of the adrenocortical axis and Cushing's syndrome.2 There have been no reports of other inhaled corticosteroids causing adrenal suppression and Cushing's syndrome. Budesonide and beclomethasone are reported to be associated with a lower risk of systemic sideeffects than fluticasone,3 and a literature review suggested that they be used as an alternative to fluticasone given the risk of suppression of the adrenocortical axis.2
We report 3 cases of children presenting with a suppressed adrenocortical axis and Cushing's syndrome as a consequence of budesonide and ritonavir co-therapy.
Case 1. A 4-year-old girl with perinatally acquired HIV infection had shown a good response to antiretroviral therapy over 29 months (HIV viral load <50 copies/ml). She received inhaled budesonide for recurrent cough and bronchodilatorresponsive wheeze and was later prescribed intranasal budesonide for allergic rhinitis. Her maximum daily dose of budesonide was 1 200 µg and her daily dose of ritonavir was 300 mg/m2. She received no other cytochrome P450 inhibitors. After 3 months of inhaled and intranasal steroid she had facial lipohypertrophy, truncal obesity and facial hirsutism. Her inhaled steroid dose was decreased to 200 µg. One week later her early-morning cortisol level was less than 1 mmol/l. All budesonide therapy was stopped. Three weeks later her earlymorning cortisol level was 222 mmol/l.
Case 2. A 4-year-old girl with perinatally acquired HIV1 infection had responded well to lopinavir/ritonavir-containing antiretroviral therapy for 30 months (HIV viral load <50 copies/ml). She was diagnosed with bronchiolitis obliterans following severe recurrent lower respiratory tract infections and was managed on 200 µg budesonide daily. Her total daily dose of ritonavir was 235 mg/m2. She developed facial and truncal obesity, facial hirsutism and a buffalo hump after 2 years on treatment with inhaled steroids. Blood pressure and blood sugar were normal. Her early-morning cortisol level was 8 mmol/l. The lopinavir/ritonavir was switched to efavirenz. Her early-morning cortisol level was 278 mmol/l when repeated 4 weeks after stopping ritonavir.
Case 3. A 7-year-old boy with perinatally acquired HIV1 infection and post-infective chronic obstructive airways disease had had a good response to antiretroviral therapy for 59 months (HIV viral load <50 copies/ml). He had symptoms of recurrent lower airway obstruction on a background of chronic obstructive airways disease following previous severe bacterial pneumonia and tuberculosis. On prescribed inhaled fluticasone 50 µg and salmeterol he developed facial and truncal obesity, a buffalo hump and facial hirsuitism within 2 months. His early-morning cortisol level was less than 1 mmol/l. Fluticasone was replaced with budesonide at 100 µg twice daily. One month after replacing fluticasone with budesonide there was no improvement in the phenotypic features and he had a persistently suppressed adrenal cortical axis (earlymorning cortisol 5 mmol/l). It is interesting to note that even with the Cushing's symptoms his recurrent respiratory signs and symptoms persisted. Two weeks after stopping inhaled steroid therapy a repeat early-morning cortisol level was 5 mmol/l, and a further 4 weeks later it was 115 mmol/l. An adrenocorticocotrophic hormone (ACTH) stimulation test showed a moderate response.
Adrenal suppression with ritonavir and concomitant fluticasone has been described in children and adolescents,2,4 and it has been suggested that other inhaled corticosteroids such as budesonide may be safer, given the comparatively prolonged clearance of fluticasone.
Our cases demonstrate that budesonide, which is also metabolised by iso-enzyme CYP3A4, can produce adrenal suppression when used with ritonavir/lopinavir. HIV-infected children have a high incidence of chronic lung disease, which includes chronic obstructive respiratory disease.5 Given the large number of children who are prescribed ritonavircontaining antiretroviral regimens, many may be exposed to co-treatment with budesonide.
The daily dose of budesonide used in our cases varied from 200 µg to 1 200 µg. Adherence to medication was assessed by verbal report and medication demonstration by the caregiver. In case 2 the child was given medication by a trained nurse in a children's home and medication was boarded for us to review. Dosing of inhaled budesonide in children with obstructive lung disease is based on clinical response to treatment. Recommended dosing ranges from a low dose of 100 -200 µg/d to higher doses of >400 µg/d. With the exception of case 1 these children were on moderate doses of budesonide only and in case 3 initially a low dose of fluticasone (50 µg/d). The fact that the children may have been overdosed cannot be entirely excluded. However, it appears that adrenal axis suppression can occur at standard recommended doses of budesonide and fluticasone when used concomitantly with ritonavir. This relationship requires further investigation.
The older nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine and stavudine remain first-line therapy in our and other resource-limited settings. These drugs are associated with lipodystrophy and truncal obesity. It is important to consider Cushing's syndrome as a differential diagnosis and that the diagnosis of adrenal suppression is not missed.6
The combination of ritonavir and inhaled corticosteroids should be avoided. If co-therapy is necessary, careful physical examination and monitoring of adrenal axis function are essential.
1. South African Department of Health. National Antiretroviral Treatment Guidelines. Pretoria: Jacana, 2004. [ Links ]
2. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008; 9: 389-396. [ Links ]
3. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457-461. [ Links ]
4. Arrington-Sanders R, Hutton N, Siberry GK. Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents. Pediatr Infect Dis J 2006; 25: 1044-1048. [ Links ]
5. Jeena PM, Coovadia HM, Thula SA, Blythe D, Buckels NJ, Chetty R. Persistent and chronic lung disease in HIV-1 infected and uninfected African children. AIDS 1998; 12: 1185-1193. [ Links ]
6. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34: 649-657. [ Links ]
Accepted 10 February 2010.
Corresponding author: D Gray (email@example.com)